Tvardi Therapeutics, Inc. provided financial and operating results for Q2 2025.
Key highlights include completion of enrollment in the REVERT IPF clinical trial and submission of an IND application for TTI-109.
The company is well-positioned with multiple Phase 2 data readouts expected in the near future.
Phase 2 Data Readouts
Topline data on track for Q4 2025 from the fully enrolled REVERT IPF Phase 2 trial.
New Clinical Candidate
IND application submitted for TTI-109 with the FDA in June 2025.
Merger Completion
Completed merger with Cara Therapeutics, becoming a publicly traded company.
- Tvardi's financial results show a $4.2 million net income for Q2 2025.
- Cash, cash equivalents, and investments increased to $41.0 million as of June 30, 2025.
- Research and development expenses decreased, while general and administrative expenses increased compared to 2024.
With upcoming milestones in Phase 2 clinical trials and a strong financial position, Tvardi Therapeutics continues to advance in the field of fibrosis-driven disease treatments.